Absorption of Nutrients

Absorption is the movement of digested nutrients, water, and electrolytes from the intestinal lumen, across the epithelial lining (mucosa), and into the blood or lymphatic circulation. It occurs predominantly in the small intestine, whose absorptive units are villi (finger-like mucosal projections) covered in enterocytes, each enterocyte in turn studded with microvilli forming the brush border. This three-tiered amplification (folds → villi → microvilli) is why the functional absorptive area so vastly exceeds the intestine's simple cylindrical geometry. Two broad transport logics operate side by side. Transcellular transport moves a solute through the enterocyte itself, crossing the luminal (apical) membrane, traversing the cytoplasm, and exiting across the basolateral membrane into the interstitial fluid, which drains into either blood capillaries or lymphatic lacteals. Paracellular transport moves solutes (chiefly water and small ions) between adjacent enterocytes, through the intercellular tight junctions, which in the small intestine are relatively "leaky" compared to more selective epithelia. Nearly every specific nutrient transporter discussed below is a transcellular, carrier-mediated mechanism; simple diffusion and paracellular flow account for water and some ion movement. The single organizing principle unifying carbohydrate, amino acid, and much of electrolyte absorption is secondary active transport driven by the Na⁺ electrochemical gradient. The enterocyte's basolateral membrane contains abundant Na⁺/K⁺-ATPase, which continuously pumps 3 Na⁺ out and 2 K⁺ in per ATP hydrolyzed, keeping intracellular Na⁺ low (~10–15 mM) against a luminal concentration around 140 mM. This gradient is then "spent" by apical membrane cotransporters that couple the energetically downhill movement of Na⁺ into the cell to the energetically uphill movement of glucose, galactose, or specific amino acids — a strategy first rigorously demonstrated by Robert Crane in 1960 and now a textbook paradigm of physiology cited well beyond the gut (renal tubule glucose reabsorption uses the identical principle).

Carbohydrate absorption. Dietary starch and disaccharides are broken down by salivary/pancreatic amylase and brush-border disaccharidases (sucrase, lactase, maltase) into the three monosaccharides the gut can absorb: glucose, galactose, and fructose. Glucose and galactose enter enterocytes via SGLT1 (sodium-glucose linked transporter 1), an apical membrane protein that binds one glucose (or galactose) molecule together with two Na⁺ ions and transports both into the cell simultaneously — a 2:1 Na⁺:sugar stoichiometry. Because Na⁺ moves down its steep electrochemical gradient, it drags glucose along even though glucose itself is moving against its own concentration gradient — this is secondary active transport, since no ATP is spent directly by SGLT1; the "payment" was made upstream by Na⁺/K⁺-ATPase. Fructose, in contrast, cannot use SGLT1; it crosses the apical membrane via GLUT5, a facilitated-diffusion transporter that requires no Na⁺ and moves fructose down its own concentration gradient (maintained low intracellularly because fructose is rapidly phosphorylated). All three monosaccharides then exit the basolateral membrane into the interstitial fluid via GLUT2, another facilitated transporter, and diffuse into the capillary network draining into the hepatic portal vein.

Protein absorption. Pancreatic proteases (trypsin, chymotrypsin, carboxypeptidases) and brush-border peptidases reduce dietary protein mostly to free amino acids and small di/tripeptides. At least seven distinct Na⁺-dependent amino acid transporters exist on the apical membrane, each with different substrate specificity (neutral, acidic, basic, or imino amino acids) — a redundancy that explains why isolated genetic defects in one transporter (e.g., Hartnup disease, affecting neutral amino acid transport) cause selective rather than global amino acid malabsorption. Remarkably, di- and tripeptides do not need to be hydrolyzed to free amino acids before absorption: the transporter PepT1 cotransports peptides together with H⁺ (not Na⁺) into the enterocyte, exploiting a local H⁺ gradient maintained by an apical Na⁺/H⁺ exchanger. Once inside the cytoplasm, cytosolic peptidases hydrolyze most di/tripeptides to free amino acids, which then exit via basolateral facilitated transporters into the portal blood. This dual-route absorption (free amino acid transporters plus PepT1) means peptide-based absorption is actually faster and quantitatively more important than once assumed — much dietary protein nitrogen is absorbed as small peptides, not solely as free amino acids.

Lipid absorption follows an entirely different logic because triglycerides and their digestion products are hydrophobic and cannot dissolve in the aqueous luminal environment or move by any transporter analogous to SGLT1. Pancreatic lipase (aided by colipase) hydrolyzes triglycerides into monoglycerides and free fatty acids. Bile salts, secreted by the liver and concentrated in bile, emulsify these lipid products and package them into mixed micelles — small (3–10 nm) aggregates with a hydrophilic shell (bile salts, phospholipids) and hydrophobic core (monoglycerides, fatty acids, fat-soluble vitamins A, D, E, K, and cholesterol). Micelles diffuse through the unstirred water layer adjacent to the brush border and release their lipid cargo, which then diffuses across the apical membrane (with some contribution from a fatty acid transport protein, FATP4, and the cholesterol transporter NPC1L1 — the pharmacological target of the drug ezetimibe). Bile salts themselves are not absorbed here; they continue down the intestine to be reabsorbed later, in the terminal ileum, via a dedicated Na⁺-dependent bile acid transporter (ASBT), completing the enterohepatic circulation. Once inside the enterocyte, monoglycerides and fatty acids are re-esterified in the smooth endoplasmic reticulum back into triglycerides, then packaged with cholesterol, phospholipids, and apolipoprotein B-48 into large lipoprotein particles called chylomicrons. These are too large to pass through capillary basement membranes, so they exit the basolateral membrane by exocytosis and enter the lacteal, a blind-ended lymphatic capillary at the core of each villus. Chylomicrons travel through the lymphatic system, into the thoracic duct, and enter the systemic venous circulation at the left subclavian vein — completely bypassing the hepatic portal vein and, initially, the liver. This lymphatic route is the single most important physiological distinction between fat absorption and the absorption of sugars/amino acids, and it explains why chylomicronemia turns post-fat-meal blood plasma visibly milky ("lactescent").

Water and electrolyte absorption. Water crosses intestinal epithelium passively, following osmotic gradients created by solute transport — there is no active water pump. Every mole of Na⁺, glucose, or amino acid absorbed transcellularly, and every mole of Na⁺/Cl⁻ absorbed paracellularly, osmotically drags water with it, both through cellular water channels (aquaporins) and through the leaky paracellular tight junctions. Sodium absorption itself uses several parallel mechanisms depending on intestinal region: Na⁺-glucose/amino acid cotransport (as above), Na⁺/H⁺ exchange coupled to Cl⁻/HCO₃⁻ exchange (electroneutral NaCl absorption, prominent in the ileum), and in the colon, epithelial Na⁺ channels (ENaC) that allow electrogenic Na⁺ absorption regulated by aldosterone. Potassium is absorbed mostly passively down concentration gradients as water absorption concentrates luminal K⁺; calcium absorption is partly active (vitamin D-dependent, via the calcium-binding protein calbindin and a basolateral Ca²⁺-ATPase) and partly passive/paracellular; iron absorption is tightly regulated by the apical transporter DMT1 and the basolateral exporter ferroportin, under systemic control by the hormone hepcidin.

The concept that glucose absorption is active — not merely diffusive — was established well before its molecular mechanism was known. In the 1950s–60s physiologists using everted intestinal sac preparations (a segment of intestine turned inside-out and incubated in glucose solution, so that the mucosal, absorptive surface faces outward into the bath) showed that intestinal tissue could accumulate glucose inside the sac to concentrations several times higher than in the surrounding bathing medium. This directly contradicted a simple-diffusion model, in which luminal-to-serosal glucose movement should stop once concentrations equalize. Crucially, this uphill glucose accumulation stopped when metabolic poisons (such as cyanide, which blocks ATP production) were added, or when the bathing medium's Na⁺ was replaced with another cation such as choline — showing that both metabolic energy and sodium were required.

Robert K. Crane synthesized these observations in 1960 into the Na⁺-glucose cotransport hypothesis: rather than glucose transport itself consuming ATP directly, he proposed that a separate ATP-driven pump maintains a Na⁺ gradient, and a single carrier protein uses the energy stored in that gradient to move glucose uphill together with Na⁺ moving downhill — the essential principle now called secondary active transport. This was a conceptual leap: it explained why abolishing the Na⁺ gradient (with ouabain, which blocks Na⁺/K⁺-ATPase, or by removing luminal Na⁺) collapsed glucose transport even though glucose metabolism itself was unaffected. Subsequent work using brush border membrane vesicles — isolated apical membrane fragments that reseal into vesicles free of cytoplasmic enzymes and organelles — confirmed the model directly: vesicles loaded with a low intracellular Na⁺ concentration, then exposed to a high extracellular Na⁺ gradient, showed a transient "overshoot" of glucose accumulation inside the vesicle to levels exceeding the final equilibrium concentration — a signature only explainable by coupled transport, since no metabolic machinery was present in the vesicle to supply independent energy. The SGLT1 protein itself was later cloned in 1987 (by Matthias Hediger and colleagues), definitively confirming the transporter's molecular identity and closing the loop between physiological prediction and molecular biology. For lipid absorption, the key historical evidence came from combining bile duct ligation/bile diversion experiments in animals with clinical observations in humans with bile salt deficiency (e.g., obstructive jaundice, ileal resection). Diverting bile away from the intestine, or chemically depleting bile salts, dramatically reduces fat absorption and produces steatorrhea (fatty, malodorous stool) even when pancreatic lipase is fully active — demonstrating that lipase alone is insufficient and that micelle formation by bile salts is a separate, necessary step. Radiolabeled fatty acid studies further showed that lymphatic duct ligation, or collection of lymph via a thoracic duct fistula in animals, intercepts nearly all absorbed long-chain fat as chylomicrons in the lymph, while medium-chain fatty acids (which do not require micelle solubilization or chylomicron packaging, being short and water-soluble enough to diffuse directly and exit basolaterally as free fatty acids bound to albumin) appear instead directly in portal blood — a clean physiological dissociation of the two absorptive routes that remains the rationale for using medium-chain triglyceride (MCT) formulas in patients with fat malabsorption syndromes. The discovery that Na⁺-coupled glucose cotransport also drives water absorption — and that this persists even during massive intestinal secretion in cholera — provided the physiological foundation for oral rehydration therapy (ORT). Cholera toxin activates the enterocyte's cAMP-driven chloride secretion but does not impair SGLT1-mediated Na⁺-glucose cotransport, which remains intact. Clinical trials in Bangladesh and India in the 1960s–70s (led by researchers including Norbert Hirschhorn, David Nalin, and Richard Cash) demonstrated that oral solutions containing glucose plus electrolytes could reverse severe cholera-induced dehydration nearly as effectively as intravenous fluids, at a fraction of the cost — a discovery the medical journal The Lancet later called possibly the most important medical advance of the 20th century, directly validating Crane's cotransport mechanism at bedside scale and saving an estimated tens of millions of lives.

Example 1 — Quantifying osmotic water absorption. A physiology experiment perfuses 1 liter of an isotonic solution containing 140 mM NaCl and 100 mM glucose through a segment of jejunum per hour, and measures that 850 mL of fluid is absorbed into the blood, along with 95% of the glucose and 90% of the Na⁺. Reasoning: Every mole of glucose absorbed via SGLT1 co-transports 2 moles of Na⁺; separately, luminal Na⁺ is absorbed by Na⁺/H⁺ exchange and paracellular pathways as well. The absorbed osmoles drive water absorption osmotically — no separate "water pump" is needed. Quantitatively:

• Glucose absorbed: 0.095 mol/L × 1 L = 0.095 mol
• Na⁺ absorbed: 0.90 × 0.140 mol/L × 1 L = 0.126 mol
• Total solute particles removed from lumen (approximating Na⁺ largely accompanied by Cl⁻, contributing roughly proportionally): well over 0.2 osmol removed from the 1 L bathing lumen.

Because the fluid absorbed (850 mL) closely tracks the solute absorbed (Na⁺ and glucose together, both entering the same interstitial compartment and raising its local osmolarity transiently), the near-linear relationship between solute uptake and water uptake is the basis for the physiological rule: water absorption in the small intestine is a passive, secondary consequence of solute absorption, not an independently regulated process. This is precisely why ORT solutions are formulated with the glucose:Na⁺ ratio close to the 1:1 to 1:2 range that maximizes SGLT1-driven cotransport (and hence water uptake) without exceeding the transporter's capacity — using too much glucose can osmotically worsen diarrhea by drawing water into the lumen instead.

Example 2 — Diagnosing a malabsorption pattern. A patient presents with chronic diarrhea, bloating specifically after dairy consumption, but normal fat and protein absorption (normal fecal fat, normal serum albumin, no steatorrhea). A hydrogen breath test after a lactose load shows a sharp rise in breath hydrogen. Reasoning: Lactose must first be hydrolyzed by the brush-border enzyme lactase into glucose and galactose before either monosaccharide can be absorbed via SGLT1 — an unhydrolyzed disaccharide cannot cross the apical membrane at all, since SGLT1 is monosaccharide-specific. If lactase activity is deficient (the common adult-onset decline in lactase expression, or "lactose intolerance"), lactose remains in the lumen, osmotically retaining water (explaining diarrhea) and passing to the colon, where bacteria ferment it, producing hydrogen gas, methane, and short-chain fatty acids (explaining bloating and the positive hydrogen breath test). Because the defect is confined to a single brush-border enzyme rather than a transporter or the pancreas, fat and protein absorption — which depend on separate enzymatic and transport systems entirely — remain unaffected, correctly localizing the lesion to lactase deficiency rather than a global malabsorption syndrome such as pancreatic insufficiency or celiac disease (villous atrophy), both of which would additionally impair fat and protein absorption.

:::warning[The most dangerous confusion is conflating "active transport" with "requires its own ATP hydrolysis at the same step."] SGLT1 and most amino acid transporters are secondary active transporters: the immediate driving force is the Na⁺ gradient, not ATP itself. Students who assume every uphill nutrient movement must be paired with direct ATP hydrolysis will misdiagnose the effect of metabolic poisons (which block the upstream Na⁺/K⁺-ATPase, indirectly collapsing all Na⁺-coupled transport) versus direct transporter inhibitors (like phlorizin, which blocks SGLT1 itself without touching the Na⁺ pump).

Absorption physiology underlies some of the most consequential public-health and clinical interventions in modern medicine. Oral rehydration therapy, built directly on SGLT1 cotransport physiology, remains a frontline treatment for diarrheal disease worldwide and is credited with preventing millions of deaths, particularly in children, at negligible cost compared to intravenous fluids. Bariatric and metabolic surgery (such as gastric bypass) deliberately reroutes nutrient flow past portions of the small intestine, altering absorption kinetics of sugar and fat and contributing to both weight loss and rapid improvement in type 2 diabetes — effects partly explained by altered nutrient delivery to distal absorptive and hormone-secreting regions. SGLT2 inhibitors (a major class of diabetes drugs, e.g., empagliflozin), though acting in the kidney rather than the gut, exploit the same transporter family logic established by intestinal SGLT1 research, blocking renal glucose reabsorption to lower blood glucose. Ezetimibe, a cholesterol-lowering drug, works by blocking the intestinal cholesterol transporter NPC1L1, directly targeting the micelle-to-enterocyte step of lipid absorption. In neonatal and clinical nutrition, medium-chain triglyceride (MCT) formulas exploit the fact that medium-chain fatty acids bypass micelle/chylomicron packaging and enter the portal vein directly, making them valuable for patients with bile salt deficiency, pancreatic insufficiency, or lymphatic disorders such as chylothorax. Agricultural and veterinary science apply the same transport principles to formulate oral electrolyte solutions for livestock with diarrheal disease, and to design enteral nutrition formulas for critically ill or premature human patients whose absorptive capacity is compromised.

Ask the tutor: How would blocking SGLT1 with a drug like phlorizin affect both glucose absorption and water absorption in the small intestine?